In the eye, a number of potential treatments to promote normal bioenergetics and preserve RGCs have recently progressed to late stage clinical trials, including Renexus® NT-501, a ciliary neurotrophic factor (CNTF) secreting implant for glaucoma (Phase II, reporting end 2023, clinicaltrials.gov), and Elamipretide, an apoptosis inhibitor that reduces the release of cytochrome C and mROS (Phase II ReSIGHT, Stealth BioTherapeutics; [97,98]), among others. Here, CNTF is linked to glaucoma.